{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:52:02Z","timestamp":1794588722239,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Neurological forms of Gaucher disease, the inherited disorder of \u03b2-Glucosylceramidase caused by bi-allelic variants in\n                      <jats:italic>GBA1,<\/jats:italic>\n                      is a progressive disorder which lacks a disease-modifying therapy. Systemic manifestations of disease are effectively treated with enzyme replacement therapy, however, molecules which cross the blood\u2013brain barrier are still under investigation. Clinical trials of such therapeutics require robust, reproducible clinical endpoints to demonstrate efficacy and clear phenotypic definitions to identify suitable patients for inclusion in trials. The single consistent clinical feature in all patients with neuronopathic disease is the presence of a supranuclear saccadic gaze palsy, in the presence of Gaucher disease this finding serves as diagnostic of \u2018type 3\u2019 Gaucher disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We undertook a study to evaluate saccadic eye movements in Gaucher patients and to assess the role of the EyeSeeCam in measuring saccades. The EyeSeeCam is a video-oculography device which was used to run a protocol of saccade measures. We studied 39 patients with non-neurological Gaucher disease (type 1), 21 patients with type 3 (neurological) disease and a series of 35 healthy controls. Mean saccade parameters were compared across disease subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We confirmed the saccadic abnormality in patients with type 3 Gaucher disease and identified an unexpected subgroup of patients with type 1 Gaucher disease who demonstrated significant saccade parameter abnormalities. These patients also showed subtle neurological findings and shared a\n                      <jats:italic>GBA1<\/jats:italic>\n                      variant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This striking novel finding of a potentially attenuated type 3 Gaucher phenotype associated with a specific GBA1 variant and detectable saccadic abnormality prompts review of current disease classification. Further, this finding highlights the broad spectrum of neuronopathic Gaucher phenotypes relevant when designing inclusion criteria for clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-020-01637-9","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T05:13:44Z","timestamp":1608182024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Eye movement biomarkers allow for the definition of phenotypes in Gaucher Disease"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2623-5233","authenticated-orcid":false,"given":"Aimee","family":"Donald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong Y.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Chakrapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralyn A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislav","family":"Bardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gorges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"1637_CR1","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s10545-009-1164-2","volume":"32","author":"A Vellodi","year":"2009","unstructured":"Vellodi A, Tylki-Szymanska A, Davies EH, Kolodny E, Bembi B, Collin-Histed T, et al. Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis. 2009;32:660\u20134. https:\/\/doi.org\/10.1007\/s10545-009-1164-2.","journal-title":"J Inherit Metab Dis"},{"key":"1637_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12235","author":"R Schiffmann","year":"2020","unstructured":"Schiffmann R, Sevigny J, Rolfs A, Davies EH, Goker-Alpan O, Abdelwahab M, et al. The definition of neuronopathic Gaucher disease. J Inherit Metab Dis. 2020. https:\/\/doi.org\/10.1002\/jimd.12235.","journal-title":"J Inherit Metab Dis"},{"key":"1637_CR3","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency\u2014macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Engl J Med. 1991;324:1464\u201370. https:\/\/doi.org\/10.1056\/NEJM199105233242104.","journal-title":"N Engl J Med"},{"key":"1637_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","volume":"82","author":"K Wong","year":"2004","unstructured":"Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004;82:192\u2013207. https:\/\/doi.org\/10.1016\/j.ymgme.2004.04.011.","journal-title":"Mol Genet Metab"},{"key":"1637_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/jnnp.40.5.470","volume":"40","author":"JH Tripp","year":"1977","unstructured":"Tripp JH, Lake BD, Young E, Ngu J, Brett EM. Juvenile Gaucher\u2019s disease with horizontal gaze palsy in three siblings. J Neurol Neurosurg Psychiatry. 1977;40:470\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1637_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.7326\/0003-4819-78-6-883","volume":"78","author":"JD Miller","year":"1973","unstructured":"Miller JD, McCluer R, Kanfer JN. Gaucher\u2019s Disease: Neurologic Disorder in Adult Siblings. Ann Intern Med. 1973;78:883\u20137. https:\/\/doi.org\/10.7326\/0003-4819-78-6-883.","journal-title":"Ann Intern Med"},{"key":"1637_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10545-009-9009-6","volume":"33","author":"A Tylki-Szyma\u0144ska","year":"2010","unstructured":"Tylki-Szyma\u0144ska A, Vellodi A, El-Beshlawy A, Cole JA, Kolodny E. Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry. J Inherit Metab Dis. 2010;33:339\u201346. https:\/\/doi.org\/10.1007\/s10545-009-9009-6.","journal-title":"J Inherit Metab Dis"},{"key":"1637_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199969289.001.0001","volume-title":"The neurology of eye movements","author":"RJ Leigh","year":"2015","unstructured":"Leigh RJ, Zee DS. The neurology of eye movements. Oxford: Oxford University Press; 2015."},{"key":"1637_CR9","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/hmg\/ddr019","volume":"20","author":"T Farfel-Becker","year":"2011","unstructured":"Farfel-Becker T, Vitner EB, Pressey SNR, Eilam R, Cooper JD, Futerman AH. Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum Mol Genet. 2011;20:1375\u201386. https:\/\/doi.org\/10.1093\/hmg\/ddr019.","journal-title":"Hum Mol Genet"},{"key":"1637_CR10","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S0959-4388(97)80149-3","volume":"7","author":"JA B\u00fcttner-Ennever","year":"1997","unstructured":"B\u00fcttner-Ennever JA, Horn AK. Anatomical substrates of oculomotor control. Curr Opin Neurobiol. 1997;7:872\u20139. https:\/\/doi.org\/10.1016\/S0959-4388(97)80149-3.","journal-title":"Curr Opin Neurobiol"},{"key":"1637_CR11","volume-title":"Types of eye movements and their functions","author":"D Purves","year":"2001","unstructured":"Purves D, Augustine GJ, Fitzpatrick D, Katz LC, LaMantia A-S, McNamara JO, et al. Types of eye movements and their functions. 2nd ed. Sunderland: Sinauer Associates; 2001.","edition":"2"},{"key":"1637_CR12","doi-asserted-by":"publisher","first-page":"e22410","DOI":"10.1371\/journal.pone.0022410","volume":"6","author":"W Benko","year":"2011","unstructured":"Benko W, Ries M, Wiggs EA, Brady RO, Schiffmann R, FitzGibbon EJ. The saccadic and neurological deficits in type 3 Gaucher disease. PLoS ONE. 2011;6:e22410. https:\/\/doi.org\/10.1371\/journal.pone.0022410.","journal-title":"PLoS ONE"},{"key":"1637_CR13","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1212\/01.wnl.0000187080.74460.89","volume":"65","author":"S Pensiero","year":"2005","unstructured":"Pensiero S, Accardo A, Pittis MG, Ciana G, Bembi B, Perissutti P. Saccade testing in the diagnosis and treatment of type 3 Gaucher disease. Neurology. 2005;65:1837. https:\/\/doi.org\/10.1212\/01.wnl.0000187080.74460.89.","journal-title":"Neurology"},{"key":"1637_CR14","unstructured":"Heide W, Koenig E, Trillenberg P, K\u00f6mpf D, Zee D. Chapter 5: Electrooculography: technical standards and applications. In: Recommendations for the practice of clinical neurophysiology: guidelines of the international federation of clinical neurophysiology, p. 223 (1999)."},{"key":"1637_CR15","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","volume":"132","author":"J Neumann","year":"2009","unstructured":"Neumann J, Bras J, Deas E, O\u2019Sullivan SS, Parkkinen L, Lachmann RH, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease. Brain. 2009;132:1783\u201394. https:\/\/doi.org\/10.1093\/brain\/awp044.","journal-title":"Brain"},{"key":"1637_CR16","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.ymgme.2017.12.085","volume":"123","author":"A Donald","year":"2018","unstructured":"Donald A, Jones SA. Is it time to redefine what it means to have type 3 Gaucher disease? Mol Genet Metab. 2018;123:S40. https:\/\/doi.org\/10.1016\/j.ymgme.2017.12.085.","journal-title":"Mol Genet Metab"},{"key":"1637_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ana.21491","volume":"64","author":"R Schiffmann","year":"2008","unstructured":"Schiffmann R, FitzGibbon EJ, Harris C, DeVile C, Davies EH, Abel L, et al. Randomized, controlled trial of miglustat in Gaucher\u2019s disease type 3. Ann Neurol. 2008;64:514\u201322. https:\/\/doi.org\/10.1002\/ana.21491.","journal-title":"Ann Neurol"},{"key":"1637_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00711","author":"T Bremova-Ertl","year":"2018","unstructured":"Bremova-Ertl T, Schiffmann R, Patterson MC, Belmatoug N, Billette de Villemeur T, Bardins S, et al. Oculomotor and vestibular findings in gaucher disease type 3 and their correlation with neurological findings. Front Neurol. 2018. https:\/\/doi.org\/10.3389\/fneur.2017.00711.","journal-title":"Front Neurol"},{"key":"1637_CR19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0140-6736(01)05490-3","volume":"358","author":"D Elstein","year":"2001","unstructured":"Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A. Gaucher\u2019s disease. Lancet. 2001;358:324\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(01)05490-3.","journal-title":"Lancet"},{"key":"1637_CR20","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher\u2019s disease. Lancet. 2008;372:1263\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(08)61522-6.","journal-title":"Lancet"},{"key":"1637_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1749-6632.2009.03858.x","volume":"1164","author":"E Schneider","year":"2009","unstructured":"Schneider E, Villgrattner T, Vockeroth J, Bartl K, Kohlbecher S, Bardins S, et al. EyeSeeCam: an eye movement-driven head camera for the examination of natural visual exploration. Ann N Y Acad Sci. 2009;1164:461\u20137. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.03858.x.","journal-title":"Ann N Y Acad Sci"},{"key":"1637_CR22","first-page":"13","volume":"3","author":"W Becker","year":"1989","unstructured":"Becker W. The neurobiology of saccadic eye movements. Metrics Rev Oculomot Res. 1989;3:13\u201367.","journal-title":"Metrics Rev Oculomot Res"},{"key":"1637_CR23","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1212\/WNL.25.11.1071","volume":"25","author":"RW Baloh","year":"1975","unstructured":"Baloh RW, Sills AW, Kumley WE, Honrubia V. Quantitative measurement of saccade amplitude, duration, and velocity. Neurology. 1975;25:1071\u20136.","journal-title":"Neurology"},{"key":"1637_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00295","author":"J Blume","year":"2017","unstructured":"Blume J, Beniaminov S, K\u00e4mpe Bj\u00f6rkvall C, Machaczka M, Svenningsson P. Saccadic impairments in patients with the Norrbottnian Form of Gaucher\u2019s disease type 3. Front Neurol. 2017. https:\/\/doi.org\/10.3389\/fneur.2017.00295.","journal-title":"Front Neurol"},{"key":"1637_CR25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s13023-019-1244-9","volume":"14","author":"S Hopf","year":"2019","unstructured":"Hopf S, Pfeiffer N, Liesenfeld M, Mengel K-E, Hennermann JB, Schmidtmann I, et al. A comprehensive monocentric ophthalmic study with Gaucher disease type 3 patients: vitreoretinal lesions, retinal atrophy and characterization of abnormal saccades. Orphanet J Rare Dis. 2019;14:257. https:\/\/doi.org\/10.1186\/s13023-019-1244-9.","journal-title":"Orphanet J Rare Dis"},{"key":"1637_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","volume":"13","author":"SE Gary","year":"2018","unstructured":"Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. Expert Rev Endocrinol Metab. 2018;13:107\u201318. https:\/\/doi.org\/10.1080\/17446651.2018.1445524.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1637_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/bjh.15402","volume":"182","author":"S Revel-Vilk","year":"2018","unstructured":"Revel-Vilk S, Szer J, Mehta A, Zimran A. How we manage Gaucher Disease in the era of choices. Br J Haematol. 2018;182:467\u201380. https:\/\/doi.org\/10.1111\/bjh.15402.","journal-title":"Br J Haematol"},{"key":"1637_CR28","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/brain\/awf168","volume":"125","author":"MR MacAskill","year":"2002","unstructured":"MacAskill MR, Anderson TJ, Jones RD. Adaptive modification of saccade amplitude in Parkinson\u2019s disease. Brain. 2002;125:1570\u201382. https:\/\/doi.org\/10.1093\/brain\/awf168.","journal-title":"Brain"},{"key":"1637_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/jnnp.48.2.172","volume":"48","author":"RO McKeran","year":"1985","unstructured":"McKeran RO, Bradbury P, Taylor D, Stern G. Neurological involvement in type 1 (adult) Gaucher\u2019s disease. J Neurol Neurosurg Psychiatry. 1985;48:172\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1637_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/diseases5010010","author":"T Roshan Lal","year":"2017","unstructured":"Roshan Lal T, Sidransky E. The spectrum of neurological manifestations associated with Gaucher disease. Diseases. 2017. https:\/\/doi.org\/10.3390\/diseases5010010.","journal-title":"Diseases"},{"key":"1637_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.beem.2014.08.007","volume":"29","author":"D Elstein","year":"2015","unstructured":"Elstein D, Alcalay R, Zimran A. The emergence of Parkinson disease among patients with Gaucher disease. Best Pract Res Clin Endocrinol Metab. 2015;29:249\u201359. https:\/\/doi.org\/10.1016\/j.beem.2014.08.007.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1637_CR32","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1093\/brain\/awq198","volume":"133","author":"M Biegstraaten","year":"2010","unstructured":"Biegstraaten M, Mengel E, Marodi L, Petakov M, Niederau C, Giraldo P, et al. Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain. 2010;133:2909\u201319. https:\/\/doi.org\/10.1093\/brain\/awq198.","journal-title":"Brain"},{"key":"1637_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10545-008-0832-y","volume":"31","author":"M Biegstraaten","year":"2008","unstructured":"Biegstraaten M, van Schaik IN, Aerts JMFG, Hollak CEM. \u2018Non-neuronopathic\u2019 Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis. 2008;31:337\u201349. https:\/\/doi.org\/10.1007\/s10545-008-0832-y.","journal-title":"J Inherit Metab Dis"},{"key":"1637_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-0004.1992.tb03618.x","volume":"41","author":"E Sidransky","year":"1992","unstructured":"Sidransky E, Tsujl S, Stubblefield BK, Gurrie J, FitzGibbon EJ, Glnns EI. Gaucher patients with oculomotor abnormalities do not have a unique genotype. Clin Genet. 1992;41:1\u20135.","journal-title":"Clin Genet"},{"key":"1637_CR35","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1136\/jmg.2004.028019","volume":"42","author":"O Goker-Alpan","year":"2005","unstructured":"Goker-Alpan O, Hruska KS, Orvisky E, Kishnani PS, Stubblefield BK, Schiffmann R, et al. Divergent phenotypes in Gaucher disease implicate the role of modifiers. J Med Genet. 2005;42:e37\u2013e37. https:\/\/doi.org\/10.1136\/jmg.2004.028019.","journal-title":"J Med Genet"},{"key":"1637_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/humu.1380030105","volume":"3","author":"E Sidransky","year":"1994","unstructured":"Sidransky E, Bottler A, Stubblefield B, Ginns EI. DNA mutational analysis of type 1 and type 3 gaucher patients: How well do mutations predict phenotype? Hum Mutat. 1994;3:25\u20138. https:\/\/doi.org\/10.1002\/humu.1380030105.","journal-title":"Hum Mutat"},{"key":"1637_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1023\/A:1012496514170","volume":"24","author":"TM Cox","year":"2001","unstructured":"Cox TM. Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis. 2001;24:107\u201323. https:\/\/doi.org\/10.1023\/A:1012496514170.","journal-title":"J Inherit Metab Dis"},{"key":"1637_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ymgme.2019.08.006","volume":"128","author":"E Ryan","year":"2019","unstructured":"Ryan E, Seehra GK, Sidransky E. Mutations, modifiers and epigenetics in Gaucher disease: blurred boundaries between simple and complex disorders. Mol Genet Metab. 2019;128:10\u20133. https:\/\/doi.org\/10.1016\/j.ymgme.2019.08.006.","journal-title":"Mol Genet Metab"},{"key":"1637_CR39","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s10545-011-9347-z","volume":"34","author":"EH Davies","year":"2011","unstructured":"Davies EH, Mengel E, Tylki-Szymanska A, Kleinotiene G, Reinke J, Vellodi A. Four-year follow-up of chronic neuronopathic Gaucher disease in Europeans using a modified severity scoring tool. J Inherit Metab Dis. 2011;34:1053\u20139. https:\/\/doi.org\/10.1007\/s10545-011-9347-z.","journal-title":"J Inherit Metab Dis"},{"key":"1637_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2015.00046","author":"S Dowiasch","year":"2015","unstructured":"Dowiasch S, Marx S, Einh\u00e4user W, Bremmer F. Effects of aging on eye movements in the real world. Front Hum Neurosci. 2015. https:\/\/doi.org\/10.3389\/fnhum.2015.00046.","journal-title":"Front Hum Neurosci"},{"key":"1637_CR41","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.visres.2005.06.011","volume":"46","author":"MS Salman","year":"2006","unstructured":"Salman MS, Sharpe JA, Eizenman M, Lillakas L, Westall C, To T, et al. Saccades in children. Vision Res. 2006;46:1432\u20139. https:\/\/doi.org\/10.1016\/j.visres.2005.06.011.","journal-title":"Vision Res"},{"key":"1637_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00221-012-3192-7","volume":"222","author":"MP Bucci","year":"2012","unstructured":"Bucci MP, Seassau M. Saccadic eye movements in children: a developmental study. Exp Brain Res. 2012;222:21\u201330. https:\/\/doi.org\/10.1007\/s00221-012-3192-7.","journal-title":"Exp Brain Res"},{"key":"1637_CR43","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s00213-017-4638-1","volume":"234","author":"CJW Connell","year":"2017","unstructured":"Connell CJW, Thompson B, Turuwhenua J, Hess RF, Gant N. Caffeine increases the velocity of rapid eye movements in unfatigued humans. Psychopharmacology. 2017;234:2311\u201323. https:\/\/doi.org\/10.1007\/s00213-017-4638-1.","journal-title":"Psychopharmacology"},{"key":"1637_CR44","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/SLA.0000000000000260","volume":"259","author":"LL Di Stasi","year":"2014","unstructured":"Di Stasi LL, McCamy MB, Macknik SL, Mankin JA, Hooft N, Catena A, et al. Saccadic eye movement metrics reflect surgical residents\u02bc fatigue. Ann Surg. 2014;259:824\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000000260.","journal-title":"Ann Surg"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01637-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-020-01637-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01637-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T05:28:25Z","timestamp":1608182905000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01637-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1637"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01637-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-37355\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-37355\/v2","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"21 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was undertaken with UK research ethics committee approval (REC: 16\/WA\/0129; Wales NHS REC Bangor; IRAS 192163) and was therefore undertaken in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All participants provided informed written consent prior to study inclusion.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants provided informed written consent prior to study inclusion which included consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No authors have any conflicts of interest with the study sponsors. ES is general manager and shareholder of EyeSeeTec GmbH.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"349"}}